ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "DPYD Variant Dosing & ICIs In Pancreatic Cancer"
Episode Synopsis
Empiric dose reductions for variant DPYD alleles isn't necessarily new, but the outcomes of patients treated with those dose reductions isn't well described. Dutch researchers provide some much needed evidence.
Link: https://pubmed.ncbi.nlm.nih.gov/?term=37639651
Is there a role for ICIs in dMMR/MSI-h pancreatic cancer? This retrospective says, uh maybe probably.
Link: https://pubmed.ncbi.nlm.nih.gov/?term=37625102
Link: https://pubmed.ncbi.nlm.nih.gov/?term=37639651
Is there a role for ICIs in dMMR/MSI-h pancreatic cancer? This retrospective says, uh maybe probably.
Link: https://pubmed.ncbi.nlm.nih.gov/?term=37625102
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust